Navigation Links
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Date:5/5/2008

Study represents first inclusion of Volcano Revolution(R) 45 MHz IVUS Imaging Catheter in large-scale pharmaceutical plaque progression trial.

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today participation in SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). This marks the first major pharmaceutical trial allowing physicians to use the Volcano Revolution(R) 45 MHz IVUS Imaging catheter as part of the protocol.

SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. This study by AstraZeneca is designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.

The SATURN study is chaired by Steve Nissen, M.D., with Steve Nichols, M.D. from the Cleveland Clinic Core Lab as the principle investigator. Under this protocol, physicians enrolling patients may select the Volcano Revolution(R) IVUS catheters as their IVUS catheter of choice.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
8. XTENT Announces First Quarter 2008 Financial Results
9. Neuralstem Announces Issuance of Core Technology Patent in Europe
10. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
11. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 /PRNewswire/ ... new products for oncology supportive care, announced that its ... been featured in an article on OncLive.com titled, "Study ... and Neck Cancers."  Dr. Steve Sonis , a ... growing demand seen in the oncology community for evidence-based ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... number of costs associated with nonprescription drug manufacturing and ... half years. Certain material costs for plastic bottles and ... time, increasing packaging expenses. Advertising and marketing expenses continue ... of marketers reduced advertising costs in 2009, and in ...
... ERES ) announced today that it will release ... 4, 2010, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
Cached Medicine Technology:Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 2Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:7/31/2014)... July 31, 2014 Eden Lew ... ‘Chuck’ Forman - Crawford Technologies" Scholarship through ... was created to honor the contributions Chuck Forman ... his industry. Chuck lost his battle with cancer ... outstanding, and we are thrilled to see her ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... Brickner; “no, not the summer’s hottest metal bands ~ ... Homeostatic Cannabinoid Science ~ Publius’ July Roundup, new ... articles are noted on homeostasis and the cannabinoid system ... modulation of our health and wellness: three directly on ...
(Date:7/31/2014)... 2014 Daily Gossip reveals in its review ... discover some breakthrough weight loss tips. , The author ... recommendations are very simple to implement. Users don’t have to ... no need to start counting calories. , The Flat ... fact created a 12 weeks weight loss program to help ...
(Date:7/31/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is looking at 11 drug addiction facts ... be. , “While some kids learn a little ... class, the coverage is typically woefully inadequate,” commented Best Drug ...
(Date:7/31/2014)... 2014 Dolce Vite Chocolatto®, world's ... in New York's favorite specialty coffee roaster and DUMBO ... for their commitment to Fair Trade coffee and was ... the new sensation from Italy as the world’s best ... highly popular Italian dessert descended from European Royalty. Prepared ...
Breaking Medicine News(10 mins):Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 2Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 3Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Dolce Vite Chocolatto® - World's Best Thick Dark Italian Hot Chocolate Now Available at NYC's Favorite Cafe Brooklyn Roasting Company 2
... and 24 are smokers, and most say they keep lighting up ... have found that when it comes to quitting, a little bit ... plan in helping women not only keep off the weight, but ... to keep their weight down and for body image reasons, and ...
... in breakthrough creativity in the DTC category, Med Ad ... Wellness as the winner of both the Most Creative ... commenting on the awards, Saatchi & Saatchi Wellness Managing ... advertising icon Helayne Spivak and I knew we needed ...
... diabetes therapy, positively influencing compliance and persistency; electronic ... of dispensing ACCU-CHEK(R) test strips.INDIANAPOLIS, April 24 ... eVoucherRx(TM) pilot program in Florida, designed to make ... their co-pay savings on ACCU-CHEK test strips. The ...
... lowers patients, financial responsibility for their diabetes therapy, ... works in real time at point of dispensing ... today the launch of its new eVoucherRx(TM) pilot ... for patients with diabetes to receive their co-pay ...
... continuing to rise even though the number of cases ... reveals. , The report entitled Cancer incidence, mortality, treatment ... 1994-2004, was compiled by the Northern Ireland Cancer Registry ... Registry (NCRI) of Ireland, in Cork. , This is ...
... help look out for seniors, welfareDETROIT, April 24 ... the lookout and help identify potentially vulnerable elderly customers ... more necessary as Michigan,s economy continues to tumble."Times are ... to do our part to help ensure people don,t ...
Cached Medicine News:Health News:Mind over muscle 2Health News:Saatchi & Saatchi Wellness Wins Creative Awards Honored At 20th Annual Manny Awards 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Survival rates for cancer rise across Ireland 2Health News:Survival rates for cancer rise across Ireland 3Health News:DTE Energy Asks Employees to Help Safeguard Customers 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: